Envair Technology, a specialist UK manufacturer of clean air and containment solutions for the healthcare, biotechnology and pharmaceutical industries, has reported an 18% year-on-year rise in international sales.
Almost 40% of the group’s total revenues at the end of FY21 came from international markets, compared with 33% at the end of the previous year. This global growth has been led primarily by its ONFAB brand, which specialises in designing, manufacturing and installing flexible isolators for the pharmaceutical process manufacturing industry.
The brand is now forecasting that it will hit several million in sales for the US market by the end of this financial year
Progress internationally has continued, with ONFAB recording a 154% rise in sales in the Americas in Q1 2022 alone, compared with the whole of 2021. ONFAB has seen substantial growth in orders from global contract and development manufacturing organisations (CDMOs) as more businesses understand the benefits of using flexible containment for existing processes.
The brand is now forecasting that it will hit several million in sales for the US market by the end of this financial year.
At the same time, the manufacturer’s Envair brand, which provides clean air solutions for the medical and drug development sectors, is enjoying expansion in Europe. It received a large increase in orders from customers in Ireland and Germany during the first quarter of 2022.
This significant international growth follows on from the group’s decision to bring more of its manufacturing processes in-house, and consolidate the production of its rigid containment and fume cupboard lines in a new facility in Heywood, Greater Manchester in order to deliver faster turnaround times.
Andrew Ellison, CEO of Envair Technology, said: “One of our key business aims is to continue expanding our presence overseas so it’s really pleasing to see new projects in the USA and Europe. We expect that the growing demand we’re seeing for containment solutions will lead to further international expansion by the end of this year.”
Mark Arnold, MD of ONFAB, said: “With high potency compounds (HPAPIs) being used more frequently in drug manufacturing processes around the world, we’re seeing a huge demand for containment solutions that will allow organisations to produce drugs faster and more flexibly. ONFAB facilitates that by enabling those companies to quickly contain production processes in a cost-effective way.”